Patients are still dying waiting for access almost one year on from 'clunky' admission

The Medical Services Advisory Committee will reconsider Janssen's CAR-T therapy CARVYKTI for multiple myeloma almost one year after Health Minister Mark Butler cited the treatment as evidence of the system's 'clunky' decision-making and the cause of unnecessary deaths. …